303 related articles for article (PubMed ID: 22466463)
21. Subfoveal choroidal thickness change after intravitreal ranibizumab for idiopathic choroidal neovascularization.
Cao XS; Peng XY; You QS; Zhang YP; Jonas JB
Retina; 2014 Aug; 34(8):1554-9. PubMed ID: 24667570
[TBL] [Abstract][Full Text] [Related]
22. Cone structure in retinal degeneration associated with mutations in the peripherin/RDS gene.
Duncan JL; Talcott KE; Ratnam K; Sundquist SM; Lucero AS; Day S; Zhang Y; Roorda A
Invest Ophthalmol Vis Sci; 2011 Mar; 52(3):1557-66. PubMed ID: 21071739
[TBL] [Abstract][Full Text] [Related]
23. Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration.
Kang HM; Kwon HJ; Yi JH; Lee CS; Lee SC
Am J Ophthalmol; 2014 May; 157(5):1013-21. PubMed ID: 24487050
[TBL] [Abstract][Full Text] [Related]
24. Intravitreal ranibizumab for pigment epithelium detachment with subfoveal occult choroidal neovascularization: a prospective 24-month case series.
Parodi MB; Iacono P; Papayannis A; Kontadakis SD; Cascavilla M; Pierro L; Gagliardi M; Bandello F
Am J Ophthalmol; 2013 Jan; 155(1):103-108.e2. PubMed ID: 23022164
[TBL] [Abstract][Full Text] [Related]
25. Association of pattern dystrophy with an HTRA1 single-nucleotide polymorphism.
Jaouni T; Averbukh E; Burstyn-Cohen T; Grunin M; Banin E; Sharon D; Chowers I
Arch Ophthalmol; 2012 Aug; 130(8):987-91. PubMed ID: 22893068
[TBL] [Abstract][Full Text] [Related]
26. Two week, OCT-based follow-up as guidance for retreatment with ranibizumab for CNV apparently refractory to therapy.
Manousaridis K; Talks J
Eur J Ophthalmol; 2015; 25(3):235-40. PubMed ID: 25449645
[TBL] [Abstract][Full Text] [Related]
27. Prognostic factors of eyes with naïve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab.
Yang HS; Kim JG; Kim JT; Joe SG
Am J Ophthalmol; 2013 Dec; 156(6):1201-1210.e2. PubMed ID: 24075429
[TBL] [Abstract][Full Text] [Related]
28. Splice site mutation in the peripherin/RDS gene associated with pattern dystrophy of the retina.
Sears JE; Aaberg TA; Daiger SP; Moshfeghi DM
Am J Ophthalmol; 2001 Nov; 132(5):693-9. PubMed ID: 11704030
[TBL] [Abstract][Full Text] [Related]
29. Phenotypic variability and long-term follow-up of patients with known and novel PRPH2/RDS gene mutations.
Renner AB; Fiebig BS; Weber BH; Wissinger B; Andreasson S; Gal A; Cropp E; Kohl S; Kellner U
Am J Ophthalmol; 2009 Mar; 147(3):518-530.e1. PubMed ID: 19038374
[TBL] [Abstract][Full Text] [Related]
30. Long-term variable outcome of myopic choroidal neovascularization treated with ranibizumab.
Cohen SY; Nghiem-Buffet S; Grenet T; Dubois L; Ayrault S; Fajnkuchen F; Delahaye-Mazza C; Quentel G; Tadayoni R
Jpn J Ophthalmol; 2015 Jan; 59(1):36-42. PubMed ID: 25416566
[TBL] [Abstract][Full Text] [Related]
31. Subfoveal Choroidal Thickness Changes Following Anti-Vascular Endothelial Growth Factor Therapy in Myopic Choroidal Neovascularization.
Ahn SJ; Park KH; Woo SJ
Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):5794-800. PubMed ID: 26325418
[TBL] [Abstract][Full Text] [Related]
32. Prognostic factors for visual outcome after intravitreal anti-VEGF injection for naive myopic choroidal neovascularization.
Yoon JU; Kim YM; Lee SJ; Byun YJ; Koh HJ
Retina; 2012 May; 32(5):949-55. PubMed ID: 22534553
[TBL] [Abstract][Full Text] [Related]
33. Intravitreal ranibizumab for predominantly hemorrhagic choroidal neovascularization in age-related macular degeneration.
Lazzeri S; Figus M; Sartini MS; Scarinci F; Casini G; Guidi G; Cupo G; Cacciamani A; Fasanella V; Agnifili L; Piaggi P; Varano M; Ripandelli G; Nardi M; Parravano M
Ophthalmologica; 2015; 233(2):74-81. PubMed ID: 25662794
[TBL] [Abstract][Full Text] [Related]
34. Changes of choroidal neovascularization in indocyanine green angiography after intravitreal ranibizumab injection.
Lee JE; Kim HW; Lee SJ; Lee JE
Retina; 2015 May; 35(5):999-1006. PubMed ID: 25590857
[TBL] [Abstract][Full Text] [Related]
35. Long-Term Changes in Submacular Choroidal Thickness after Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration: 14-Mo Follow-Up.
Inan S; Baysal Z; Inan UU
Curr Eye Res; 2019 Aug; 44(8):908-915. PubMed ID: 30909756
[No Abstract] [Full Text] [Related]
36. Multifocal electroretinography and optical coherence tomography changes after repeated intravitreal bevacizumab (Avastin) in myopic choroidal neovascularization.
Sabry D; Gad MA; Enam KM
Retina; 2013 Mar; 33(3):598-605. PubMed ID: 23064427
[TBL] [Abstract][Full Text] [Related]
37. Combination therapy with intravitreal tissue plasminogen activator and ranibizumab for subfoveal type 2 choroidal neovascularization.
Kachi I; Yasukawa T; Kato A; Takase N; Morita H; Kubota A; Hirano Y; Uemura A; Ogura Y
Jpn J Ophthalmol; 2016 May; 60(3):179-86. PubMed ID: 26919844
[TBL] [Abstract][Full Text] [Related]
38. Recurrence of SRF Post Intravitreal Ranibizumab for Pediatric Choroidal Neovascularisation Secondary to Best Disease.
Subbiah D; Hashim H; Chew FLM
Ocul Immunol Inflamm; 2020 Oct; 28(7):1149-1151. PubMed ID: 31509457
[TBL] [Abstract][Full Text] [Related]
39. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.
Sharma S; Toth CA; Daniel E; Grunwald JE; Maguire MG; Ying GS; Huang J; Martin DF; Jaffe GJ;
Ophthalmology; 2016 Apr; 123(4):865-75. PubMed ID: 26783095
[TBL] [Abstract][Full Text] [Related]
40. Intravitreal Ranibizumab for myopic choroidal neovascularization after pars plana vitrectomy and silicone oil tamponade.
Cascavilla ML; Querques G; Querques L; Codenotti M; Bandello F
Eur J Ophthalmol; 2013; 23(6):913-6. PubMed ID: 23813105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
